semaglutide compulsive behavior Do New Obesity and Diabetes Drugs Also Curb Drinking, Gambling, and Other Addictions? | BU Today Understanding Semaglutide's Role in OCD

Phase III clinical data from SCENESSE trials (the FDA-approved formulation of afamelanotide) demonstrated that patients with erythropoietic protoporphyria achieved clinically meaningful photoprotection after 60 days of sustained drug delivery via controlled-release implant

Combination approaches pairing GLP-1 drugs with myostatin inhibitors (to preserve muscle) or with other metabolic targets are being explored

This pattern repeats at every dose increase, and understanding it prevents unnecessary worry

The TGA has confirmed it is currently investigating this, including reviewing relevant medical literature and international adverse event reports

Look for clear dosing disclosure, third-party testing transparency, and avoidance of drug-like promises